上海市医药集中招标采购事务管理所近日发布通知，因企业未按照要求调整药品价格，即日起暂停安徽 长江药业有限公司（以下简称长江药业）生产的盐酸多巴酚丁胺注射液和吉林省辉南长龙生化药业股份 有限公司（以下简称辉南长龙）生产的盐酸精氨酸注射液两款药品的采购资格。两款药品均为短缺药 品，除了上述两家企业外，两款药品在国内均已有多家企业拿到了批准文号。 据上海市医药集中招标采购事务管理所通知，被暂停采购资格的共两款药品，即长江药业生产的盐酸多 巴酚丁胺注射液（规格为2ml:20mg*1支/支，玻璃安瓿）和辉南长龙生产的盐酸精氨酸注射液（规格为 20ml:5g*1支/支，安瓿）。 我国对短缺药品的管理机制正日趋完善。早在2019年，国务院办公厅印发《关于进一步做好短缺药品保 供稳价工作的意见》，医疗保障部门坚决落实短缺药品直接挂网的采购政策。对于列入国家和省有关部 门短缺和易短缺清单的药品，本着"有药可用优先、保障治疗优先"的原则，各省医药集中采购机构接受 企业自主涨价、一路绿灯。国家医保局指出，政策实施以来，国家短缺和易短缺清单内药品供应形势明 显改善，平均配送到位率从2019年以前约60%提升至目前的90%。但也出现了 ...

Core Viewpoint - The suspension of procurement qualifications for two critical shortage drugs, Dobutamine Hydrochloride Injection and Arginine Hydrochloride Injection, due to failure to reduce prices, highlights the ongoing challenges in ensuring supply and stabilizing prices in the shortage drug market [1][2][10]. Group 1: Drug Details - Dobutamine Hydrochloride Injection, produced by Anhui Changjiang Pharmaceutical, is essential for treating acute heart failure and is packaged in 2ml:20mg vials [3][4]. - Arginine Hydrochloride Injection, produced by Jilin Province Huinan Changlong Biochemical Pharmaceutical, is crucial for treating hepatic encephalopathy and is packaged in 20ml:5g vials [3][4]. - The average national price for Dobutamine Hydrochloride Injection is reported at 3.53 yuan per unit, while Arginine Hydrochloride Injection is at 11.68 yuan per unit [9]. Group 2: Market Dynamics - The recent price increases for shortage drugs, including the significant rise in the price of the rare disease drug Hydrocortisone Acetate Tablets, reflect ongoing supply and demand imbalances, regulatory challenges, and regional price disparities [2][10][12]. - The production of Dobutamine Hydrochloride Injection is not limited to Anhui Changjiang Pharmaceutical; other companies like Hainan Puli Pharmaceutical and Shandong Xinhua Pharmaceutical have also entered the market, enhancing competition [5][6]. - The procurement suspension serves as a warning to pharmaceutical companies that they must consider drug accessibility and price rationality in their pricing strategies to avoid market constraints [9][11]. Group 3: Regulatory Environment - The regulatory landscape for shortage drugs has evolved from self-pricing to risk management, with recent policies allowing companies to set reasonable prices while emphasizing the need to prevent unreasonable price hikes and monopolistic practices [11][12]. - Various regions, including Chongqing and Guangdong, are exploring centralized procurement for shortage and emergency drugs to stabilize prices and ensure supply [12].